Success Predictors of Endoscopic Sleeve Gastroplasty

Objective Endoscopic sleeve gastroplasty (ESG) is a minimally invasive procedure that proved to be safe and effective in obesity treatment. However, not all subjects respond to treatment in the same way, and, with a view to personalized care, it is essential to identify predictors of success or fail...

Full description

Saved in:
Bibliographic Details
Published in:Obesity surgery 2024-05, Vol.34 (5), p.1496-1504
Main Authors: Matteo, Maria Valeria, Bove, Vincenzo, Ciasca, Gabriele, Carlino, Giorgio, Di Santo, Riccardo, Vinti, Laila, Polidori, Giulia, Pontecorvi, Valerio, Papi, Massimiliano, Spada, Cristiano, Boškoski, Ivo
Format: Article
Language:English
Subjects:
Body mass index
Diabetes
Endoscopy
Ethics
Female
Females
Gastrointestinal surgery
Gastroplasty - methods
Humans
Lifestyles
Male
Males
Medicine
Medicine & Public Health
Metabolism
Multidisciplinary teams
Obesity
Obesity - surgery
Obesity, Morbid - surgery
Original Contributions
Postoperative period
Quality of life
Retrospective Studies
Success
Surgery
Sutures
Treatment Outcome
Trends
Weight control
Weight Loss
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective Endoscopic sleeve gastroplasty (ESG) is a minimally invasive procedure that proved to be safe and effective in obesity treatment. However, not all subjects respond to treatment in the same way, and, with a view to personalized care, it is essential to identify predictors of success or failure. Methods A retrospective 2-year followed-up cohort of ESG subjects was analyzed to investigate the presence of any baseline or early indicators of long-term optimal or suboptimal ESG outcomes. Results A total of 315 subjects (73% women) were included, with 73% of patients exhibiting an Excess weight loss percentage (%EWL) >25% at the 24 months. Neither demographic parameters (age and sex), smoking habits, and menopause in women nor the presence of comorbidities proved potential predictive value. Interestingly, the %EWL at 1 month after ESG was the strongest predictor of 24-month therapeutic success. Subsequently, we estimated an “early threshold for success” for 1 month-%EWL by employing Youden’s index method. Conclusions ESG is a safe and effective bariatric treatment that can be offered to a wide range of subjects. Early weight loss seems to impact long-term ESG results significantly and may allow proper early post-operative care optimization. Graphical Abstract
ISSN:0960-8923
1708-0428
DOI:10.1007/s11695-024-07109-4